Anti-Adenovirus Type 5 antibody (ab6982)

ab6982 has been referenced in 19 publications.

1. Ross PJ et al. Assembly of helper-dependent adenovirus DNA into chromatin promotes efficient gene expression. J Virol 85:3950-8 (2011). PubMed: 21307207
2. Guedan S et al. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 18:1275-83 (2010). IHC-P, IHC-Fr. PubMed: 20442708
3. Soria C et al. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 466:1076-81 (2010). PubMed: 20740008
4. Willemsen RA et al. Multi-component polymeric system for tumour cell-specific gene delivery using a universal bungarotoxin linker. Pharm Res 27:2274-82 (2010). ELISA. PubMed: 20300804
5. Ingemarsdotter CK et al. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 29:6051-63 (2010). WB. PubMed: 20729921
6. Smith AC et al. DNA genome size affects the stability of the adenovirus virion. J Virol 83:2025-8 (2009). WB. PubMed: 19036812
7. O'Prey J et al. The tumor antigen LRRC15 impedes adenoviral infection - implications for viral-based cancer therapy. J Virol : (2008). PubMed: 18385238
8. Peixoto C et al. Towards purification of adenoviral vectors based on membrane technology. Biotechnol Prog 24:1290-6 (2008). WB. PubMed: 19194943
9. Miakotina OL et al. Human adenovirus modulates surfactant phospholipid trafficking. Traffic 8:1765-77 (2007). PubMed: 17897321
10. Sebestyen Z et al. An oncolytic adenovirus redirected with a tumor-specific T-cell receptor. Cancer Res 67:11309-16 (2007). PubMed: 18056457
11. Li X et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 13:5463-73 (2007). PubMed: 17875776
12. Cascallo M et al. Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses. Hum Gene Ther 17:929-40 (2006). PubMed: 16972761
13. Majem M et al. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD. Cancer Gene Ther 13:696-705 (2006). PubMed: 16498429
14. Subramanian T et al. Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 80:2000-12 (2006). WB. PubMed: 16439556
15. Schepelmann S et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res 65:5003-8 (2005). WB. PubMed: 15958540
16. Sargent KL et al. Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. J Virol 78:5032-7 (2004). WB. PubMed: 15113884
17. Campos SK et al. Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther 9:942-54 (2004). PubMed: 15194061
18. Spector DJ et al. Adenovirus type 5 DNA-protein complexes from formaldehyde cross-linked cells early after infection. Virology 312:204-12 (2003). PubMed: 12890633
19. Sprangers MC et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41:5046-52 (2003). PubMed: 14605137